Summary The metastasis-suppressor nme gene (also called nm23), first identified in murine melanoma cells, exists as two forms in human: nmel and nme2. However, only the lack of expression of nmel has been related to distant metastasis appearance in human breast cancer. The aim of this work was first to raise specific antibodies to allow the analysis of Nmel and then, with this specific tool, to evaluate the predictive value (Kimura and Shimada, 1988 ) but the precise molecular mechanism underlying the role of nme genes in metastasis dissemination is still unclear. The metastasis-suppressor activity of nmel seems to be correlated more with serine phosphorylation of Nmel protein (MacDonald et al., 1993) than with kinase activity (Sastre-Garau et al., 1992) . A recent report (Howlett et al., 1994) suggests that nmel may play an important role in the differentiation of human breast cancer. Moreover, Postel et al. (1993) has suggested that the Nme2 protein is a transcription factor for the c-myc oncogene.
The metastasis-suppressor gene, nmel was identified in 1988 (Steeg et al., 1988) by differential hybridisation between low and high metastatic murine melanoma cell lines: the mRNA expression of this gene was found to be higher in the low metastatic cell line. In human, the nme gene family consists of two closely related genes: nmel and nme2, which respectively code for two different subunits (A and B) of nucleotide diphosphate kinases (NDP kinases) (Gilles et al., 1991) . These two subunits, which show more than 88% homology, associate together in different ratios according to tissue location, to form hexameric NDP kinases. This class of enzymes is involved in microtubule association (Nickerson and Wells, 1991) and G-protein regulation (Kimura and Shimada, 1988 ) but the precise molecular mechanism underlying the role of nme genes in metastasis dissemination is still unclear. The metastasis-suppressor activity of nmel seems to be correlated more with serine phosphorylation of Nmel protein (MacDonald et al., 1993) than with kinase activity (Sastre-Garau et al., 1992) . A recent report (Howlett et al., 1994) suggests that nmel may play an important role in the differentiation of human breast cancer. Moreover, Postel et al. (1993) has suggested that the Nme2 protein is a transcription factor for the c-myc oncogene.
The predictive value of nme detection has been evaluated by several authors in human tumours. Reduced expression of nmel has been found in ovarian carcinomas (Mandai et al., 1994) , in hepatocellular carcinoma (Nakayama et al., 1992; Yamaguchi et al., 1994; Boix et al., 1994) , in metastatic lymph nodes from patients with papillary carcinoma of the thyroid (Arai et al., 1993) and in metastasis of malignant melanoma (Xerri et al., 1994) . Conflicting results have been obtained in colorectal tumorigenesis: Yamaguchi (1993) obtained lower amounts of nmel mRNA and protein in colorectal tumours associated with liver metastasis than in those without such metastasis while Myeroff et al. (1993) showed an increase of the mRNA level in both high-and low-metastatic potential tumours, suggesting that the activity of the nme gene could be tissue specific. In breast cancer a low level of nmel mRNA has been correlated with a high metastatic potential (Henessy et al., 1991; Bevilacqua et al., 1989) to a greater extent than nme2 (Stahl et al., 1991 (Figure 3 ) and to overall survival (P<0.001) (Figure 4 ).
Discussion
The results published by Steeg (1988) The c-erbB-2 oncogene, which encodes for a transmembrane glycoprotein with high homology with epidermal growth factor receptor, is amplified in 15-30% of breast cancer. This overexpression has been found to be related to an increase in the proliferative activity of the tumour and by some authors to a shorter survival (Wright et al., 1989; Tandon et al., 1989; Rilke et al., 1991) . More recently, an overexpression of c-erbB-2 has been associated to the response to chemotherapy (Muss et al., 1994) . A significant relationship between the expression of c-erbB-2 and the mRNA level of nmel has been shown in ovarian carcinomas (Mandai et al., 1994) ; this relationship was also observed by immunohistochemical staining of sections for nme products and c-erbB-2. On the contrary, Slamon (1991) reported that human breast and ovarian carcinoma cell lines transfected with HER2/neu exhibited reduced nme mRNA levels. In our population, an overexpression of c-erbB-2 was observed in 17% of tumours but no significant relationship between cerbB-2 and Nmel expression could be demonstrated. Furthermore, Nmel expression was independent of another metastasis predictive factor, cathepsin D levels, suggesting that the metastasis process involving Nmel protein could be different from that of cathepsin D.
We have described here highly significant relationships between Nmel expression and metastasis-free survival (P<0.001) and specific survival (P<0.001). These results obtained at the level of protein expression using our antibody are in agreement with several studies analysing nmel mRNA levels in breast cancer (Henessy et al., 1991) and in other locations (Arai et al., 1993) . Although this approach needs to be confirmed by a larger study, it underlines the interesting role of specifically detecting cytosolic nmel for the prediction of metastasis outcome in breast cancer. 
